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Abstract
BACKGROUND: Patients who are diagnosed with trisomy 13 (Patau syndrome) are known to have a poor 
prognosis. It has been hypothesized that such poor outcomes are suspected to be attributed to their central nervous 
system (CNS)-malformations and cardiac-malformations. This study was conducted at Division of Neuropediatric, 
Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran – Dr. Hasan Sadikin Hospital, Bandung 
(2012–2018). 
AIM: This study aimed to describe clinical characteristics and karyotype findings in patients who were diagnosed with 
Patau syndrome and treated at our center. Since Indonesia is still categorized as a lower middle-income country with 
limited resources, we expected that this study would provide a clinical reference on how a congenital disease with 
chromosomal abnormalities is confirmed.
CASE PRESENTATION: Our cases indicate that CNS malformations are likely to be the cause of indirect mortality of 
patients’ early period of life. The median survival in our study is 7 days, while the longest survival is 30 days. The major 
cause of death is apnea, which found in 4 of 5 diagnosed infants. One patient died of severe infection. In most cases, 
where CNS malformations were observed microcephaly with sloping forehead, Dandy–Walker syndrome, lobar or 
alobar holoprosencephaly and ventriculomegaly were identified, as well as neural tube defects (NTDs) were identified, 
such as spina bifida and meningoencephalocele. CNS malformations, such as holoprosencephaly, may be associated 
with episodes characterized by temporary cessation of spontaneous breathing (apnea) as direct cause of mortality. 
CONCLUSION: We conclude that early treatment in Patau syndrome patient in our center should be focused on 
more life-threatening problem caused by CNS malformations than NTDs defects, such defects could be managed 
electively.
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Introduction
Patau syndrome is an incurable congenital 
disease, characterized by malformation of body parts, 
and impaired intellectual capacities. In the majority of 
the cases, karyotyping identifies trisomy of chromosome 
13. However, a duplication of part(s) of chromosome 13 
and mosaicism has also been acknowledged in some 
patients, thus resulting in the diversity of phenotypes 
of Patau syndrome. Therefore, it is not surprising if 
phenotype and karyotype findings in patients who are 
diagnosed with Patau syndrome have kept scientists 
and clinicians intrigued. In lower- to middle-income 
countries like Indonesia, diagnosis and treatment of 
congenital diseases such as Patau syndrome are 
still challenging. Apart from difficulties such as the 
unavailability of a medical specialist in clinical genetics 
and the overwhelming number of patients treated with 
related specialists on a daily basis, limited resources 
added another layer of challenges in making diagnosis 
and treating patients with Patau syndrome. This is 
how we describe our experiences in establishing 
diagnosis of patients with Patau syndrome. To the 
best of our knowledge, there is no preceding report 
regarding the clinical characteristics, and karyotype 
findings in Indonesia, especially in Bandung have ever 
been released. The aim of this study is to provide an 
insight regarding the management of Patau syndrome 
from the case series of Patau syndrome at our center. 
The correlation of trisomy 13 to this syndrome was 
first described by Patau et al. in 1960 [1]. Most infants 
with Patau syndrome have a high mortality; the median 
survival around 4 days old [2]. Malformations of the 
central nervous system (CNS) and cardiac have been 
suggested as main attribute of death caused in patients 
with Patau syndrome. A thorough study on the clinical 
characteristics would also be useful to evaluate the 
true cause of death among patients who are diagnosed 
with Patau syndrome, particularly in patients who were 
diagnosed and treated at our center.
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Case Presentation
This is a case series study performed in 
a single center: Faculty of Medicine, Universitas 
Padjadjaran (FK UNPAD) – Dr. Hasan Sadikin Hospital 
(RSHS), Bandung. Patients suspected of having Patau 
syndrome were initially admitted to the department of 
pediatrics or neurology before being consulted to the 
department of neurosurgery. When necessary, the 
diagnosis was confirmed the cytogenetic examination. 
Data were collected from patients who were suspected 
of having Patau syndrome, in the period of 2012–
2018. The inclusion criteria were patients with clinical 
phenotype of Patau syndrome and having been 
confirmed of having trisomy of chromosome 13. Since 
karyotyping is not covered by our national insurance 
coverage, not all patients who were suspected with 
Patau syndrome could be included in this study. 
They were around 15 patients suspected with Patau 
syndrome, which was admitted during the study period; 
most clinical examinations reveal as microcephaly, cleft 
lip and palate, and low set ears. Clinical characteristics 
and karyotype findings were constructed from patients’ 
medical record.
Five patients with Patau syndrome who had 
their diagnosis confirmed at the period of 2012 to 2018 
were included in this study (Table 1): 
Patient #1. was born a term from P2A1 mother 
(37–38 weeks of gestation), with multiple congenital 
anomaly (posterior meningioencephalocele rupture, 
microcephaly, right microphtalmia, immature retina at 
the left eye, short neck, labiopalatoschisis, and low 
set ear); karyotype as 47, XY, +13 (Figure 1), and 
imaging evaluations shown a dextrocardia, right lung 
dysgenesis, and spina bifida at the corpus of thoracic 
vertebra 1, 2, and 3; open wound care as treatment 
for meningioencephalocele rupture with antibiotics 
therapy for infection occurred and respiratory failure 
complications (Figure 2) treated in neonatology 
intensive care unit with poor prognosis; and apnea as 
cause of death.
Patient #2. was born a term from P1A0 mother 
(37–38 weeks of gestation); with multiple congenital 
anomaly (microcephaly with sloping forehead, widely 
set eyes, labiopalatoschisis, omphalocele); karyotype 
as 47, XX, +13, and imaging evaluations shown 
polydactyl; complications from sepsis neonatorum 
treated in neonatology intensive care unit with poor 
prognosis; and severe infection as cause of death.
Figure 1: Representative results of karyotyping of Trisomy 13. 
Chromosomes images obtained from cover slide glass, with three 
sets of chromosome 13 are shown with arrows (a). Reported 
rearrangement of the total chromosomes showed that the patient 
has a total of 47 chromosomes, including three complete copies of 
chromosome 13 shown in the red circle (b)
Patient #3. was born a term from P1A0 mother 
(37–38 weeks of gestation), with Dandy–Walker 
syndrome and seizure; karyotype as 47, XY, +13, and 
imaging evaluations shown hypoplasia of the vermis, 
cystic dilatation of the fourth ventricle, and enlarged 
posterior fossa with torcular-lambdoid inversion; 
respiratory failure complications treated in neonatology 
intensive care unit with poor prognosis; and apnea as 
cause of death.
Figure 2: Identified clinical features showed sloping forehead 
microcephaly, a broad flat nose, widely set eyes with posterior 
meningioencephalocele rupture, right microphtalmia, absent of 
eyebrows (white arrow), immature retina at the left eye, short neck, 
labiopalatoschisis, abnormal low set of ears (red circle) (a). Radiological 
feature showing dextrocardia, right lung dysgenesis, unclear renal 
contour and spina bifida of corpus vertebra thoracal 1,2,3 (b)
ba
Patient #4. was born aterm from P5A2 
mother (38 weeks of gestation), with microcephaly, 
microphthalmia, labiopalatoschisis, and low set ears; 
karyotype as 47, XX, +13, and imaging evaluations 
shown lobar holoprosencephaly (Figure 3) and 
ventriculomegaly; respiratory failure complications 
treated in neonatology intensive care unit with poor 
prognosis; and apnea as cause of death. 
Patient #5. was born premature from P3A1 
mother (35 weeks of gestation), with microcephaly with 
Table 1: Clinical characteristics of five patients who were diagnosed with trisomy 13; phenotypes findings was shown below
No. Gender Year 
admitted
Age when 
karyotyped (days)
Survival rate 
(days)
Clinical phenotypes
1 Male 2012 6 7 Posterior Meningioencephalocele Rupture + Multiple Congenital Anomaly (Microcephaly, Right Microphtalmia, Immature 
Retina at the left eye, Short Neck, Labiopalatoschisis, Low Set Ear, Dextrocardia, Right Lung Dysgenesis, Spina Bifida at 
the Corpus of Thoracic Vertebra 1,2,3), Respiratory Failure (cause of death: Apnea)
2 Female 2016 3 5 Microcephaly with sloping forehead, Widely Set Eyes, Labiopalatoschisis, Omphalocele, Polydactyl, Sepsis Neonatorum 
(cause of death: Severe infection)
3 Male 2017 21 30 Dandy–Walker Syndrome, Seizure, Respiratory Failure (cause of death: Apnea)
4 Female 2017 6 7 Microcephaly, Lobar Holoprosencephaly, Ventriculomegaly, Microphtalmia, Labiopalatoschisis, Low Set Ears, Respiratory 
Failure (cause of death: Apnea)
5 Male 2018 2 3 Microcephaly with sloping forehead, Alobar Holoprosencephaly, Ventriculomegaly, Labiopalatoschisis, Ambiguous Genitalia, 
Respiratory Failure (cause of death: Apnea)
a b
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trisomy 13 [7]. Halder et al. reported mosaic trisomy 13 
in a fetus with iniencephaly, anencephaly, facial clefts, 
single umbilical artery, dilated right cardiac atrium, 
ventricle, and clubfoot [8]. Several studies have shown 
that NTDs are acquired in approximately 8% of trisomy 
13 cases [2], [5], [9]. Rodriguez et al. revealed spina 
bifida in three out of 34 patients diagnosed with trisomy 
13 (8.8%).9 Wyllie et al. identified meningocele in one 
patient, while encephalocele in two patients, in among 
36 patients, diagnosed with trisomy 13 (8.33%) [2]. In 
our study, holoprosencephaly (lobar and alobar) with 
ventriculomegaly was identified in 2 live-born patients. 
All infants were presented with CNS malformations and 
died between 3 and 30 days of life. The cause of death 
in four out of five patients was recurrent apnea. Sepsis 
was found in the other patients whose apnea was not 
identified. Cyanosis was identified in three patients, 
which was attributed to the congenital heart defects 
and cardiopulmonary arrest. Medical examinations and 
nursing notes confirmed the presences of inadequate 
breathing in all patients.
In several studies, the median survival for live-
born children with trisomy 13 is 7–10 days, about 90% 
die within the 1st year, with the majority (approximately 
80%) dying within the 1st month of life. However, longer 
survival is possible. There are published cases of 
patients with trisomy 13 who are over 5 years of age. 
Lower frequency of heart defects may contribute to 
the longer survival. In a Canadian cohort, the mean 
1-year survival was 19.8%, and 10-year survival was 
12.9%. Most deaths occurred in the first 3 months 
of life [10], [11], [12], [13]. When a routine head USG 
findings suspect the presence of trisomy 13 in a fetus, 
confirmation of the diagnosis of trisomy 13 can be 
acquired by prenatal genetic screening. Until now, there 
is no specific therapy or treatment for patients with 
trisomy 13. Thus, the prognosis of infants with trisomy 
13 is extremely poor, while the majority of patients are 
stillborn (stillbirth). The average survival by the age of 
patients with trisomy 13 is 2.5 days, while only one in 
20 infants live longer than 6 months [3]. Usually, the 
non-interventional paradigm of providing supportive 
treatment has been recommended for trisomy 13 since 
the high mortality of the disorder, the severe intellectual 
disability in those that survive beyond 1 year of age, and 
the lack of a cure. However, acceptance of this paradigm 
is not universal because survival beyond infancy is 
possible, particularly in those who receive intensive 
treatment. In a Canadian cohort study, 29 of the 41 
children who underwent surgeries ranging survived for 
at least 1 year after the first surgery [14], [15].
To the best of our knowledge, this is the first 
case series study of trisomy 13 in Indonesia. Our study 
observed NTDs surgery, such as cele resection, to 
correct encephalocele, meningioencephalocele, or 
myelomeningocele. Despite intensive managements, 
including medications, Patau syndrome patients 
showed no significant improvement in survival. Since 
sloping forehead, labiopalatoschisis, and ambiguous 
genitalia; karyotype results 47, XY, +13, and imaging 
evaluations shown alobar holoprosencephaly 
(Figure 3) and ventriculomegaly; respiratory failure 
complications treated in neonatology intensive care 
unit with poor prognosis; and apnea as cause of death. 
Despite clinical managements, all patient-reported 
in our study died between 3 and 30 days after birth. 
The median survival age of our reported study was 7 
days, and despite the presence of CNS-malformations 
and cardiac-malformations, the cause of death in four 
patients was cardiopulmonary arrest, while the severe 
infection was acknowledged in one patient.
Figure 3: CT scan showed anomali such sloping forehead microcephaly, 
alobar holoprosencephaly (a) or lobar holoprosencephaly (b) with 
ventriculomegaly and labiopalatoschisis
Discussion
Patau syndrome is a congenital disorder which 
is caused by non-disjunction of chromosome 13 during 
meiosis in 1 of the 2 gametes, resulting in complete 
or partial trisomy of chromosome 13. To date, Patau 
syndrome has a prevalence of 1:8000–12,000 live 
births [2], [3]. The phenotype of trisomy 13 patients 
may vary in accordance with the findings whether the 
chromosome defect is complete or partial and whether 
it occurs in all cells or in some cells (mosaicism). Severe 
malformations involving multiple organs, including 
microcephaly, cyclopia, abnormal nasal structures, 
cleft lip and palate, low set ears, cardiac defect, and 
polydactyly have been described, as clinical features 
found in trisomy 13 patients. Furthermore, it has also 
been associated with neural tube defects (NTDs), such 
as encephalocele, anencephaly, and spina bifida. In 
a study performed in 2000–2011 as population-based 
registries of 16 European countries, the prevalence of 
cardiac malformations was 57% (51–64%) and CNS 
malformations were 39% (33–46%). Boys were less 
likely to have CNS malformations than girls (OR = 0.46 
[0.27–0.77]) [4].
Byrne and Warburton identified trisomy 
13 in an aborted embryo with encephalocele [5]. A 
study by Seller discovered that 8% of patients with 
trisomy 13 had spina bifida [6]. Phadke and Thakur 
reported prenatal diagnosis of iniencephaly, alobar 
holoprosencephaly, and cyclopia in a fetus with mosaic 
a b
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cardiopulmonary arrest was the cause-of-death in four 
out of five of our patients, we concluded that the major 
factors for long-term survival of patients with trisomy 13 
are an active resuscitation that performed immediately 
after birth, as well as definitive surgical treatments when 
required, such as tracheotomy and closure of NTDs.
In conclusion, our study described a case 
series of five patients who were diagnosed with Patau 
syndrome at our center. The cases particularly focused 
on CNS malformations in patients with trisomy. Since 
definitive interventions are not yet available, it is natural 
for clinicians to focus on NTDs that are identified in 
trisomy 13 patients. Nonetheless, our data suggest 
that despite any neurosurgical interventions, patients 
with trisomy 13 still die at an early period in life. These 
indicate that the CNS malformations are indirectly 
responsible for mortality in patients during their early 
period in life; therefore, neurosurgical intervention 
should not be the initial priority. Our study suggests that 
the initial treatment of trisomy 13 patients in our center 
should be focused to treat or prevent any emerging 
respiratory failure.
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